西地尼布联合奥拉帕利对比奥拉帕利治疗复发性铂敏感卵巢癌的随机II期研究的总生存期和更新无进展生存期结果
这项随机、开放标签、II期研究纳入90例复发性铂敏感卵巢癌患者,随机接受奥拉帕利单药或西地尼布联合奥拉帕利治疗。更新分析显示联合组中位无进展生存期仍显著长于单药组(16.5 vs 8.2个月,HR 0.50,P=0.007);在gBRCA野生型/未知亚组中,联合组无进展生存期和总生存期均显著改善,但总生存期在总体人群中无统计学差异。
要点
- 联合组中位无进展生存期16.5个月,单药组8.2个月,HR 0.50,P=0.007
- gBRCA野生型/未知亚组中位无进展生存期联合组23.7个月 vs 单药组5.7个月,P=0.002
- gBRCA野生型/未知亚组中位总生存期联合组37.8个月 vs 单药组23.0个月,P=0.047
核心结论
- 在复发性铂敏感卵巢癌中,西地尼布联合奥拉帕利较奥拉帕利单药显著延长无进展生存期。
- 亚组分析提示该获益幅度由无gBRCA突变患者的无进展生存期延长所驱动。
- 在该亚组中,西地尼布联合奥拉帕利也使总生存期显著增加。
- 该联合方案的进一步研究正在进行中,并应纳入基于BRCA状态的分析。
研究设计与样本
- 随机、开放标签、II期研究,2011年10月至2013年6月在美国九家学术中心入组90例患者。
- 数据截止日期为2016年12月21日,中位随访46个月。
- 入组患者为复发性铂敏感卵巢癌,组织学为高级别浆液性或子宫内膜样,或携带有害胚系BRCA1/2突变(gBRCAm)。
- 患者随机接受奥拉帕利胶囊400 mg每日两次,或西地尼布30 mg每日一次联合奥拉帕利胶囊200 mg每日两次,直至疾病进展。
主要发现
- 更新分析中,联合组中位无进展生存期仍显著长于单药组(16.5 vs 8.2个月,风险比0.50;P=0.007)。
- 在gBRCA野生型/未知患者中,联合组无进展生存期(23.7 vs 5.7个月,P=0.002)和总生存期(37.8 vs 23.0个月,P=0.047)均获统计学显著改善。
- 总体研究人群中,联合组与单药组总生存期无统计学差异(44.2 vs 33.3个月,风险比0.64;P=0.11)。
- 在gBRCAm患者中,两臂的无进展生存期和总生存期表现相似。
- 联合组最常见的CTCAE 3/4级不良事件仍为乏力、腹泻和高血压。
关键数值与推荐
- 总体人群:联合组中位无进展生存期16.5个月 vs 单药组8.2个月,风险比0.50,P=0.007。
- gBRCA野生型/未知亚组:联合组中位无进展生存期23.7个月 vs 单药组5.7个月,P=0.002。
- gBRCA野生型/未知亚组:联合组中位总生存期37.8个月 vs 单药组23.0个月,P=0.047。
- 总体人群:联合组中位总生存期44.2个月 vs 单药组33.3个月,风险比0.64,P=0.11。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Olaparib is a poly(ADP-ribose) polymerase inhibitor and cediranib is an oral anti-angiogenic. In the primary analysis of this phase II study, combination cediranib/olaparib improved progression-free survival (PFS) compared with olaparib alone in relapsed platinum-sensitive ovarian cancer. This updated analysis was conducted to characterize overall survival (OS) and update PFS outcomes. PATIENTS AND METHODS: Ninety patients were enrolled to this randomized, open-label, phase II study between October 2011 and June 2013 across nine United States-based academic centers. Data cut-off was 21 December 2016, with a median follow-up of 46 months. Participants had relapsed platinum-sensitive ovarian cancer of high-grade serous or endometrioid histology or had a deleterious germline BRCA1/2 mutation (gBRCAm). Participants were randomized to receive olaparib capsules 400 mg twice daily or cediranib 30 mg daily and olaparib capsules 200 mg twice daily until disease progression. RESULTS: In this updated analysis, median PFS remained significantly longer with cediranib/olaparib compared with olaparib alone (16.5 versus 8.2 months, hazard ratio 0.50; P = 0.007). Subset analyses within stratum defined by BRCA status demonstrated statistically significant improvement in PFS (23.7 versus 5.7 months, P = 0.002) and OS (37.8 versus 23.0 months, P = 0.047) in gBRCA wild-type/unknown patients, although OS was not statistically different in the overall study population (44.2 versus 33.3 months, hazard ratio 0.64; P = 0.11). PFS and OS appeared similar between the two arms in gBRCAm patients. The most common CTCAE grade 3/4 adverse events with cediranib/olaparib remained fatigue, diarrhea, and hypertension. CONCLUSIONS: Combination cediranib/olaparib significantly extends PFS compared with olaparib alone in relapsed platinum-sensitive ovarian cancer. Subset analyses suggest this margin of benefit is driven by PFS prolongation in patients without gBRCAm. OS was also significantly increased by the cediranib/olaparib combination in this subset of patients. Additional studies of this combination are ongoing and should incorporate analyses based upon BRCA status. TRIAL REGISTRATION: Clinicaltrials.gov Identifier NCT0111648.
引用
- Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019. PMID: 30753272. doi:10.1093/annonc/mdz018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。